0
经验分子式（希尔表示法） C22H22FN7O
分子量 419.45
This compound was developed by Pfizer for Kinase Phosphatase Biology research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.
To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Sold for research purposes under agreement from Pfizer Inc.
PF-5006739 is a potent inhibitor of casein kinases 1 delta (CK1δ) and 1 epsilon (CK1ε), key regulators of the suprachiasmatic nucleus (SCN) central clock and also linked to the development of drug addiction through PERIOD proteins (PER1–3) and dopamine- and cAMP-regulated neuronal phosphoprotein (DARPP-32) modulation. PF-5006739 has low nM in vitro potency for CK1δ/ε (IC50 values of 3.9 nM for CK1δ and 17.0 nM for CK1ε) and high kinome selectivity. PF-5006739 induced profound phase delays in circadian periodicity in both nocturnal and diurnal animal models and attenuated opioid drug-seeking behavior in a rodent operant reinstatement model.
| assay | ≥98% (HPLC) |
| form | powder |
| color | white to beige |
| solubility | DMSO: soluble10 mg/mL, clear |
| originator | Pfizer |
| storage temp. | room temp |
温馨提示:因厂家更改产品包装、产地或者更换随机附件等没有任何提前通知，且每位咨询者购买情况、提问时间等不同，为此以下回复仅对提问者3天内有效，其他网友仅供参考！若由此给您带来不便请多多谅解，谢谢！
服务热线
0771-3293894
新浪微博
腾讯微博
QQ空间
客服
